NCT00226954View on ClinicalTrials.gov

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

February 28, 2009

Conditions
Urologic Neoplasms
Interventions
DRUG

zoledronic acid

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Stanford University

OTHER

NCT00226954 - Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter